

requesting approval for export to Italy of the animal drug Interceptor® (milbemycin oxime) dye-free tablets for dogs.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of non-food animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-295-8617.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement,

the agency is providing notice that Ciba-Geigy Animal Health, Ciba-Geigy Corp., P.O. Box 18300, Greensboro, NC 27419-8300, has filed an application requesting approval for export to Italy of the animal drug Interceptor® (milbemycin oxime) dye-free tablets. The product is intended for use in dogs for prevention of heartworm disease and control of certain intestinal worm infections. The application was received and filed in the Center for Veterinary Medicine on January 12, 1993, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by February 8, 1993, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.44).

Dated: January 19, 1993.

Robert Farrow,

Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 93-1965 Filed 1-26-93; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 91E-0492 et al.]

Determination of Regulatory Review Period for Purposes of Patent Extension for Certain Products; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting several notices of determination of the regulatory review period for purposes of patent extension, for certain products. The previous Federal Register notices contained mathematical errors caused by an inadvertent error in a computer program to calculate the regulatory review period. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1382.

SUPPLEMENTARY INFORMATION: The table below lists the product name, the docket number, and the Federal Register citation corresponding to the notice of determination of regulatory review period for the product, and the corrections to the notices.

Recalculation of Regulatory Review Period

Product name	Docket number	Federal Register citation	Correction
Accupril®	91E-0492	57 FR 4212, February 4, 1992.	In FR Doc. 92-2633, on page 4212, in the 3d column in the 2d complete paragraph, in line 3, "3,441" is corrected to read "3,443"; in line 4, "2,414" is corrected to read "2,415"; and in line 6, "1,027" is corrected to read "1,028".
Bladin®	92E-0063	57 FR 10907, March 31, 1992.	In FR Doc. 92-7319, on page 10907, in the 2d column, in the 2d complete paragraph, in line 3, "2,248" is corrected to read "2,248" and "1,566" is corrected to read "1,567"; and in line 6, "680" is corrected to read "681".
Zithromax®	92E-0027	57 FR 10907, March 31, 1992.	In FR Doc. 92-7262, on page 10908, in the 2d column, in the 1st complete paragraph, in line 3, "2,560" is corrected to read "2,562"; in line 4, "1,991" is corrected to read "1,992"; and in line 6, "568" is corrected to read "570".
Foscavir®	92E-0026	57 FR 12832, April 13, 1992.	In FR Doc. 92-8398, on page 12832, in the 3d column, in the 3d complete paragraph, in line 3, "1,709" is corrected to read "1,711"; in line 4, "1,337" is corrected to read "1,338"; and in line 6, "372" is corrected to read "373".
ZOCOR®	92E-0060	57 FR 12935, April 14, 1992.	In FR Doc. 92-8553, on page 12936, in the 1st column, in the 2d complete paragraph, in line 3, "2,493" is corrected to read "2,492" and "964" is corrected to read "962"; and in line 6, "1,529" is corrected to read "1,530".

Recalculation of Regulatory Review Period—Continued

Product name	Docket number	Federal Register citation	Correction
Dermatop®	91E-0476	57 FR 13746, April 17, 1992.	In FR Doc. 92-8872, on page 13747, in the 1st column, in the 1st complete paragraph, in line 3, "3,532" is corrected to read "3,534"; in line 4, "1,450" is corrected to read "1,451"; and in line 6, "2,082" is corrected to read "2,083".
Penetrex®	92E-0083	57 FR 14418, April 20, 1992.	In FR Doc. 92-8995, on page 14418, in the 3d column, in the 1st complete paragraph, in line 3, "3,352" is corrected to read "3,354"; in line 4, "1,458" is corrected to read "1,459"; and in line 6, "1,894" is corrected to read "1,895".
RELAFEN®	92E-0084	57 FR 14728, April 22, 1992.	In FR Doc. 92-9285, on page 14729, in the 1st column, in the 2d complete paragraph, in line 3, "4,220" is corrected to read "4,222"; in line 4, "2,077" is corrected to read "2,078"; and in line 6, "2,143" is corrected to read "2,144".
Mazicon®	92E-0082	57 FR 14729, April 22, 1992.	In FR Doc. 92-9270, on page 14730, in the 1st column, in the 1st complete paragraph, in line 3, "2,557" is corrected to read "2,559"; in line 4, "2,182" is corrected to read "2,183"; and in line 6, "375" is corrected to read "376".
Palmaz Balloon-Expandable Stent®	92E-0012	57 FR 15319, April 27, 1992.	In FR Doc. 92-9738, on page 15319, in the 3d column, in the 2d complete paragraph, in line 4, "1,575" is corrected to read "1,577" and "823" is corrected to read "824"; and in line 6, "752" is corrected to read "753".
Acel-Imune®	92E-0115	57 FR 18887, May 1, 1992.	In FR Doc. 92-10141, on page 18888, in the 1st column, in the 2d complete paragraph, in line 3, "2,002" is corrected to read "2,004".
Acel-Imune®	92E-0115	57 FR 22773, May 29, 1992.	In FR Doc. 92-12547, on page 22773, in the 3d column, in line 1, "434" is corrected to read "435"; and in line 2, "1,568" is corrected to read "1,569".
Maxaquine®	92E-0131	57 FR 18888, May 1, 1992.	In FR Doc. 92-10142, on page 18889, in the 1st column, in the 1st complete paragraph, in line 3, "1,486" is corrected to read "1,488"; in line 4, "916" is corrected to read "917"; and in line 6, "570" is corrected to read "571".
Lorabid®	92E-0081	57 FR 18889, May 1, 1992.	In FR Doc. 92-10190, on page 18889, in the 3d column, in the 2d complete paragraph, in line 3, "1,697" is corrected to read "1,699"; in line 4, "1,206" is corrected to read "1,207"; and in line 6, "492" is corrected to read "493".
Meta II, Model 1204 Cardiac Pacing System®	92E-0004	57 FR 20495, May 13, 1992.	In FR Doc. 92-11127, on page 20496, in the 2d column, in the 1st complete paragraph, in line 4, "448" is corrected to read "449" and "zero" is corrected to read "0"; in line 7, "448" is corrected to read "449".
Aredia®	92E-0025	57 FR 20693, May 14, 1992.	In FR Doc. 92-11271, on page 20694, in the 2d column in the 1st complete paragraph, in line 3, "1,583" is corrected to read "1,585" and "904" is corrected to read "905"; and in line 6, "679" is corrected to read "680".
Zolof®	92E-0107	57 FR 20694, May 14, 1992.	In FR Doc. 92-11371, on page 20695, in the 1st column, in the 2d complete paragraph, in line 3, "3,997" is corrected to read "3,999" and "2,641" is corrected to read "2,642"; in line 6, "1,356" is corrected to read "1,357".
Mivacron®	92E-0156	57 FR 23235, June 2, 1992.	In FR Doc. 92-12845, on page 23236, in the 2d column, in the 1st complete paragraph, in line 3, "2,755" is corrected to read "2,757"; in line 4, "2,245" is corrected to read "2,246"; and in line 6, "510" is corrected to read "511".
Ticlid® (Patent No. 4,051,141)	92E-0023	57 FR 23238, June 2, 1992.	In FR Doc. 92-12847, on page 23238, in the 2d column, in the 2d complete paragraph, in line 3, "5,487" is corrected to read "5,489" and "4,772" is corrected to read "4,773"; and in line 6, "715" is corrected to read "716".
Ticlid® (Patent No. 4,591,592)	92E-0024	57 FR 23238, June 2, 1992.	In FR Doc. 92-12848, on page 23239, in the 2d column, in the 2d complete paragraph, in line 3, "5,487" is corrected to read "5,489" and "4,772" is corrected to read "4,773"; and in line 6, "715" is corrected to read "716".
Omniflox®	92E-0169	57 FR 23414, June 3, 1992.	In FR Doc. 92-12941, on page 23414, in the 2d column, in the 3d complete paragraph, in line 3, "1,449" is corrected to read "1,451"; in line 4, "658" is corrected to read "659"; and in line 6, "791" is corrected to read "792".
Iamox®	92E-0144	57 FR 25040, June 12, 1992.	In FR Doc. 92-13844, on page 25041, in the 1st column, in the 3d complete paragraph, in line 3, "2,878" is corrected to read "2,880" and "1,157" is corrected to read "1,158"; and in line 6, "1,721" is corrected to read "1,722".

Recalculation of Regulatory Review Period—Continued

Product name	Docket number	Federal Register citation	Correction
ADSOL® Red Cell Preservation Solution System	92E-0154	57 FR 22227, July 21, 1992.	In FR Doc. 92-17063, on page 32228, in the 1st column, in the 1st complete paragraph, in line 4, "1,192" is corrected to read "1,194"; in line 5, "496" is corrected to read "497"; and in line 7, "896" is corrected to read "897".
CPD Blood-Pack®	92E-0151	57 FR 32228, July 21, 1992.	In FR Doc. 92-17064, on page 32228, in the 3d column, in the 2d complete paragraph, in line 3, "1,192" is corrected to read "1,194"; in line 4, "496" is corrected to read "497"; and in line 6, "896" is corrected to read "897".
Cetaz®	92E-0080	57 FR 33665, July 31, 1992.	In FR Doc. 92-18110, on page 33968, in the 1st column, in the 1st complete paragraph, in line 3, "2,248" is corrected to read "2,250", and "1,615" is corrected to read "1,616"; and in line 6, "633" is corrected to read "634".

Dated: January 6, 1993.

Stuart L. Nightingale,

Associate Commissioner for Health Affairs,

[FR Doc. 93-1966 Filed 1-26-93; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Cancer Institute; Meeting (President's Cancer Panel Special Commission on Breast Cancer)

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the President's Cancer Panel Special Commission on Breast Cancer, National Cancer Institute, February 23, 1993, at the Hotel Washington, Washington Room, 515 15th Street, NW., Washington, DC 20004-1006.

This meeting will be open to the public from 8:30 a.m. to approximately 5 p.m. Attendance will be limited to space available. Agenda items will include presentations by invited speakers on the topic of "New Product Development and the Role of the Biotechnology Industry."

Iris J. Schneider, Acting Executive Secretary, President's Cancer Panel Special Commission on Breast Cancer, National Cancer Institute, Building 31, room 4A34, National Institutes of Health, Bethesda, Maryland 20892, 301/496-1148, will provide a roster of the Commission members and substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Iris J. Schneider, 301/496-1148 in advance of the meeting.

Dated: January 19, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93-1917 Filed 1-26-93; 8:45 am]

BILLING CODE 4160-01-M

National Institute of Mental Health; Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Extramural Science Advisory Board of the National Institute of Mental Health in February 1993.

This meeting will be open to the public as indicated below for discussion of the NIMH grant portfolio.

Ms. Joanna L. Kieffer, Committee Management Officer, National Institute of Mental Health, Parklawn Building, room 9-105, 5600 Fishers Lane, Rockville, MD 20857, Area Code 301, 443-4333, will provide a summary of the meeting and a roster of committee members.

Other information pertaining to the meeting may be obtained from the contact person indicated.

Committee Name: Extramural Science Advisory Board, NIMH.

Contact: Andrea Baruchin, Ph.D., 17C-26, Parklawn Building, Telephone: 301, 443-3657.

Meeting Date: February 22-23, 1993

Place: Building 31, Conference Room 8, National Institutes of Health, 9000 Wisconsin Avenue, Bethesda, MD 20892.

Open:

February 22, 1993, 8:30 a.m.-5 p.m.

February 23, 1993, 8:30 a.m.-adjournment.

(Catalog of Federal Domestic Assistance Program Numbers 93.126, Small Business Innovation Research; 93.176, ADAMHA Small Instrumentation Program Grants; 93.242, Mental Health Research Grants; 93.281, Mental Research Scientist Development Award and Research Scientist Development Award for Clinicians; 93.282, Mental Health Research Service Awards for Research Training; and 93.921, ADAMHA Science Education Partnership Award.)

Dated: January 19, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93-1918 Filed 1-26-93; 8:45 am]

BILLING CODE 4160-01-M

Prospective Grant of Exclusive License: Type Alpha Platelet-Derived Growth Factor (PDGF) Receptor Gene

AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(91) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application SN 07/308,282, entitled "Type Alpha Platelet-Derived Growth Factor Receptor Gene" to COR Therapeutics, Inc., of South San Francisco, California. The patent rights in this invention have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license will be limited to all therapeutic and diagnostic fields of use of the receptor. These fields of use are expected to include: Cardiovascular medicine; central nervous system conditions; wound healing; inflammatory and proliferative conditions; and cancer. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. If the prospective exclusive license is granted to COR Therapeutics, licenses for the use of the PDGF receptor for internal research purposes of its sale as a research reagent would still be available from the NIH.

The patent application describes novel DNA segments that encode platelet-derived growth factor (PDGF)